elililly

$BSU

Eli Lilly's Q4 2025 results confirm a massive 43% revenue surge to $19.3 billion, $GWEI

fueled by explosive volume growth in Mounjaro and Zepbound. Both exceeded analyst estimates, as did the **$7.54 adjusted EPS**. The optimistic 2026 revenue guidance ($80B–$83B) reflects sustained global demand for its GLP-1 therapies, solidifying Lilly's market leadership in weight-loss medicine.
#EliLilly

🚨 #HEADLINE :
📈ELI LILLY
SEES 2026 REV. $80B TO $83B, EST. $77.71B

#EliLilly #Earnings #Revenue

💥 NVIDIA & Eli Lilly Invest $1B in AI Lab to Transform Drug Discovery
NVIDIA and Eli Lilly have announced a joint AI lab with a $1 billion investment over five years to revolutionize drug discovery and pharmaceutical manufacturing.
📌 Key Highlights:
• The lab will leverage advanced AI models and high-performance compute infrastructure to accelerate drug development.
• Goal: Create continuous AI-assisted experimental systems linking wet labs and dry labs, shortening development cycles and enhancing molecule validation.
• Combines Lilly’s pharma expertise and proprietary data with NVIDIA’s AI technologies, including digital twins, robotics, and advanced analytics.
• Focused on optimizing pharma manufacturing, clinical operations, and drug discovery pipelines.
This partnership bridges AI and biotech, promising faster, smarter, and more efficient approaches to bringing new medicines to patients.
#NVIDIA #EliLilly #DrugDiscovery #PharmaInnovation #Biotech #HealthcareTech

🚨 JUST IN: ELI LILLY HITS A $1 TRILLION MARKET CAP A HISTORIC FIRST FOR HEALTHCARE 💊🚀

Eli Lilly just became the first healthcare company in history to touch the $1 trillion valuation mark — breaking the long-standing dominance of tech giants and Berkshire in the trillion-dollar club.

What’s driving it?
🔥 Blockbuster obesity drugs
🔥 Massive demand for GLP-1 therapies
🔥 A decade of heavy R&D finally paying off
🔥 Healthcare innovation becoming a Wall Street powerhouse

#EliLilly #USJobsData #USStocksForecast2026 #BTCVolatility #Investing $BTC $WLD $EIGEN

State Street Pushes into Crypto as Eli Lilly Stock Slips on FDA Delay

Eli Lilly's stock price experienced a significant drop on January 15, 2026, after reports of an FDA review delay for its oral GLP-1 weight-loss pill, orforglipron. The new target action date for the drug's approval is reportedly April 10, 2026.
Simultaneously, State Street has launched a new institutional digital asset platform to support tokenization services and crypto custody.

State Street's Crypto Push
Platform Launch: State Street, the world's second-largest custody bank, has rolled out a new institutional digital asset platform.
Services: The platform moves beyond back-office support, offering wallet management, custody, cash products (tokenized deposits, stablecoins), and support for tokenized money market funds and ETFs.

Strategic Shift: This launch signifies a strategic move from experimentation to scalable solutions in the digital asset space, partnering with firms like Taurus for technology to help institutions embrace tokenization with confidence.

FDA Delay for Eli Lilly's GLP-1
Delayed Review: The FDA has extended the review period for Eli Lilly's promising oral obesity drug candidate, orforglipron.

Impact on Stock: Following the news, Eli Lilly (LLY) shares slipped nearly 5% on Thursday, January 15, 2026.

New Timeline: The internal regulatory documents suggest a target action date of April 10, 2026, pushing back previous expectations for a Q1 2026 approval. The company's CFO noted they are on track for a Q2 2026 approval.

#StateStreetGlobal

#crypto

#EliLilly

#FDAApproval

#StrategyBTCPurchase